Beverly Caraway, APRN
Psychiatric/Mental Health · Batesville, ARNPI 1598737249
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations.
Across 194 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$738
- AbbVie$696
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$574
- Otsuka America Pharmaceutical, Inc.$249
- Takeda Pharmaceuticals U.S.A., Inc.$235
- Teva Pharmaceuticals USA, Inc.$204
- plus $742 from 8 others
What the payments were for
- Food & beverage$3,32997%
- Education$1083%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 46 | $738 |
| AbbVie | 43 | $696 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $574 |
| Otsuka America Pharmaceutical, Inc. | 12 | $249 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $235 |
| Teva Pharmaceuticals USA, Inc. | 13 | $204 |
| Alkermes, Inc. | 9 | $203 |
| Axsome Therapeutics, Inc. | 9 | $165 |
| Sunovion Pharmaceuticals Inc. | 9 | $143 |
| Lundbeck LLC | 9 | $141 |
| Neurocrine Biosciences, Inc. | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Merck | 1 | $15 |
| Eisai Inc. | 1 | $11 |
How this compares
$3,437 in reported general payments places this provider in the 85th percentile of 359 psychiatric/mental health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 76 | $116,237 |
| CaplytaLumateperone Tosylate | 51 | $88,915 |
| Abilify MaintenaAripiprazole | 19 | $57,826 |
| Invega SustennaPaliperidone Palmitate | 14 | $54,776 |
| RexultiBrexpiprazole | 21 | $45,104 |
| Paliperidone ErPaliperidone | 66 | $9,890 |
| TrintellixVortioxetine Hydrobromide | 12 | $8,902 |
| Aripiprazole | 170 | $7,930 |
| Lurasidone Hcl | 65 | $6,986 |
| Bupropion XlBupropion Hcl | 213 | $5,776 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 80 | $5,099 |
| Quetiapine Fumarate | 304 | $5,012 |
| Duloxetine Hcl | 250 | $4,619 |
| Doxepin Hcl | 105 | $3,529 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 155 | $3,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $696 | $116,23776 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $249 | $102,93040 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $574 | $88,91551 claims |
| Johnson & JohnsonInvega Sustenna | $738 | $54,77614 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $235 | $8,90212 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $204 | $1,13427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 359 psychiatric/mental health providers in Arkansas.
Other psychiatric/mental health in Batesville
- Kristy AdamsBatesville$7K
- Stephanie BohannonFayetteville$32K
- Michael BelinSherwood$30K
- Sarah RamseySearcy$12K
- Mallori LevengoodPine Bluff$11K
- Jennifer PenneFayetteville$11K
- Stephanie ParishSearcy$9K
- Elizabeth HardyTexarkana$8K
- Tammy HawkinsJonesboro$8K
- Cara MeckfesselLittle Rock$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.